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ABSTRACT
Background: In non-small cell lung cancer (NSCLC) KRAS-mutant status is a 
negative prognostic and predictive factor. Nitrogen-containing bisphosphonates 
inhibit prenylation of small G-proteins (e.g. Ras, Rac, Rho) and thus may affect 
proliferation and migration. In our preclinical work, we investigated the effect of an 
aminobisphosphonate compound (zoledronic acid) on mutant and wild type KRAS-
expressing human NSCLC cell lines.
Results: We confirmed that zoledronic acid was unable to inhibit the prenylation 
of mutant K-Ras unlike in the case of wild type K-Ras. In case of in vitro proliferation, 
the KRAS-mutant human NSCLC cell lines showed resistance to zoledronic acid wild-
type KRAS-cells proved to be sensitive. Combinatory application of zoledronic acid 
enhanced the cytostatic effect of cisplatin. Zoledronic acid did not induce significant 
apoptosis. In xenograft model, zoledronic acid significantly reduced the weight of 
wild type KRAS-EGFR-expressing xenograft tumor by decreasing the proliferative 
capacity. Futhermore, zoledronic acid induced VEGF expression and improved in vivo 
tumor vascularization.
Materials and methods: Membrane association of K-Ras was examined by 
Western-blot. In vitro cell viability, apoptotic cell death and migration were measured 
in NSCLC lines with different molecular background. The in vivo effect of zoledronic 
acid was investigated in a SCID mouse subcutaneous xenograft model.
Conclusions: The in vitro and in vivo inhibitory effect of zoledronic acid was 
based on the blockade of cell cycle in wild type KRAS-expressing human NSCLC cells. 
The zoledronic acid induced vascularization supported in vivo cytostatic effect. Our 
preclinical investigation suggests that patients with wild type KRAS-expressing NSCLC 
could potentially benefit from aminobisphosphonate therapy.
INTRODUCTION
Lung cancer is the lead neoplastic cause of death, 
furthermore, both incidence and mortality show constant 
elevation [1]. As one of the most aggressive neoplastic 
diseases, overall survival including stage III and stage 
IV patient groups is less than 5% within five years [2]. 
Treatment opportunities for non-small cell lung cancer 
(NSCLC) were very limited, traditionally the first option 
was surgical resection, where available, complementing 
cisplatin-based cytostatic therapy [3]. The situation 
has completely changed with the appearance of target 
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based therapy: small molecule EGFR-TKIs (e.g. 
gefitinib, erlotinib) have effects on cancer cells that 
carry the activating mutation of EGFR [4]. Nevertheless, 
disorders in the EGFR-signal can impact the efficacy of 
chemotherapy. For instance, mutant KRAS is a negative 
prognostic and predictive factor of both classic and 
target based therapy, links to poor survival and increased 
progression. Moreover, adenocarcinomas expressing 
mutant KRAS show resistance against small tyrosine 
kinase inhibitors, gefitinib and erlotinib [4]. According 
to the recent guidelines, before administration of EGFR-
TKI the mutational status of KRAS as well as EGFR is 
required to be examined [5].
The mutation of RAS-oncogene can be found in 
a variety of tumor types, its frequency is 30% in lung 
cancers [6]. Ras proteins are small GTP-binding proteins 
that affect cell proliferation, migration and survival [7]. 
The activating mutations of KRAS affect three of the 
four EGFR-pathways, the PI3K-, BRAF- and PLC-
signals [8]. The active wild type Ras is localized in 
the plasma membrane, which requires prenylation by 
farnesyltransferases or geranylgeranyltransferases [9]. 
This posttranslational modification might be blocked 
by inhibition farnesyl-diphosphate synthase, the key 
enzyme of cholesterol synthesis [10]. Prenylation-
inhibitory nitrogen-containing bisphosphonates (NBPs) 
and statins are promising candidates for clinical 
therapy of patients with cancer, albeit originally other 
indications were accepted [11]. Nitrogen-containing 
bisphosphonates (e.g. zoledronic acid) preventing bone-
metastasis inhibit a key enzyme, farnesyl diphosphonate 
(FPP) synthase in the biosynthetic mevalonate pathway, 
which interferes with numerous essential functions 
of osteoclasts [12]. Several steps of this pathway are 
required for the post-translational modification of small 
G-proteins. These macromolecules (e.g. Ras, Rac, Rho) 
play crucial role in the regulation of cell proliferation, 
survival, and migration [13].
Numerous previous studies suggested the 
antitumor activities of NBPs not only in bone metastases 
but directly on the primary tumor [14]. Preclinical 
works proved that NBPs inhibited proliferation and 
induced apoptosis in human myeloma, breast cancer, 
pancreatic cancer, prostate cancer, small and non-small 
cell lung cancer, and osteosarcoma cell lines in dose- 
and time-dependent manner [15–21]. Furthermore, in 
combination zoledronic acid with traditional cytostatic 
agent, paclitaxel showed synergistic effect on breast 
cancer cells [22]. Many animal models supported direct 
anticancer effect of NBPs: combinatorial treatment 
enhanced the effect of cytostatic therapy on the growth 
of human primary breast cancer, pancreatic cancer 
and non-small cell cancer [23–25]. Moreover, isolated 
clinical cases were described the effect of zoledronic 
acid in monotherapy, for instance, in a patient with 
pulmonary adenocarcinoma, the treatment caused 
regression of the primary lesion as well as hepatic 
metastasis [26].
Previous in silico and in vitro studies confirmed 
the antitumor effect of NBPs on EGFR-driven cancers 
[27, 28], albeit beside the EGFR itself the inhibition of 
RAS is seemed to be still another important target. The 
exact mechanism of latter still remains unclear. In the 
present study we provide several lines of evidence that 
the antiproliferative effect of zoledronic acid depends on 
the KRAS-status of human NSCLC-lines, mutant KRAS 
showed resistance, while wild type KRAS could be 
inhibited in vitro as well as in vivo affecting proliferation 
and growth of the tumor. On the contrary, migratory 
capacity proved independent of KRAS-status of human 
NSCLC lines.
RESULTS
Zoledronic acid had different effects on mutant 
and wild type KRAS
Prenylated and unprenylated form of K-Ras was 
detected in previously treated and control NSCLC 
cancer cell lines with different molecular background. 
LCLC-103H cells express wild type KRAS and wild 
type EGFR, A549 and H358 express mutant KRAS, 
H1650 cells express activated mutation in EGFR, H1975 
cells express resistant mutation in EGFR (Table 1). Cell 
suspensions were separated into cytosol and membrane 
fractions by ultracentrifuge, latter represented and 
immunoblotting revealed that in A549 and H358 cells 
25 μM zoledronic acid could not affect membrane-
association of exon2-mutant K-Ras protein. In contrast, 
in double wild type LCLC-103H cells zoledronic acid 
treatment significantly reduced membrane association 
of K-Ras, as well as H1975 with resistance mutation 
in EGFR, nevertheless adjusting to Na/K-ATPase 
latter showed only 50% decrease. Surprisingly, EGFR-
mutant cell line H1650 did not show effect on K-Ras 
(Figure 1).
Effect of zoledronic acid on the proliferation of 
human NSCLC cell lines
As detailed above, H1650, H1975 and LCLC-103H 
cell lines express wild type KRAS, while A549 and H358 
cells express mutant KRAS. After 48 hour treatment with 
different concentrations of zoledronic acid, A549 and 
H358 cells expressing mutant KRAS exhibited resistance. 
On the other hand, human NSCLC cell lines expressing 
wild type KRAS proved to be sensitive against zoledronic 
acid in dose dependent manner. The most sensitive cell 
line was LCLC-103H (wild type KRAS and EGFR). The 
maximal effect on the proliferation was approximately 
40% of untreated control (100%) at 100 μM of zoledronic 
acid (Figure 2A).
Oncotarget79505www.impactjournals.com/oncotarget
Table 1: Oncogenic mutations in the applied human NSCLC-lines 
NSCLC-lines KRAS EGFR
LCLC-103H wt wt
A549 G12S wt
H358 G12C wt
H1650 wt delE746-A750
H1975 wt L858R /T790M
H1975 is inherently resistant to EGFR inhibitors as it carries the resistance mutation T790M (in italics) besides the activating 
mutation L858R.
Figure 1: The effect of zoledronic acid on the prenylation of human NSCLC cell lines with mutant and wild type 
KRAS. Cell suspensions were separated into membrane and cytosol fractions by ultracentrifuge. Western blot confirmed that compared to 
control (C), treatment with 25 μM zoledronic acid (Z) could not modify membrane-association of mutant K-Ras in H358 and A549, while 
in LCLC-103H prenylation of wild type K-Ras was inhibited. H1975 cells showed approx. 50 percentage decrease, while zoledronic acid 
did not inhibit prenylation of wild type K-Ras in H1650 cells. Na/K-ATPase was applied as loading control.
Figure 2: The effect of zoledronic acid on the proliferation and migration of human NSCLC cell lines. Mutant KRAS-
expressing H358 and A549 showed resistance against zoledronic acid, while the treatment reduced the proliferation capacity of cell lines 
with wild type KRAS A. The inhibitory effect of zoledronic acid was less dependent of KRAS-status B. (Data are mean ± SD, n=6). *: 
p<0.05 to untreated control.
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Zoledronic acid had low apoptotic potential in 
human NSCLC cell lines
After 48 hour treatment with different concentrations 
of zoledronic acid the apoptotic sub-G1 fractions were 
stained by propidium-iodide. Flow cytometric analysis 
showed that the LCLC-103H cell line was the most 
sensitive in this respect as well. Compared to the total 
events it was found that 100 μM of zoledronic acid 
increased the percentage apoptosis to almost 10%. In case 
of H1650 a relatively high level of basic apoptosis was 
measured (untreated control), and a significantly increased 
apoptotic level for zoledronic acid was not observable. 
In case of H1975 zoledronic acid induced statistically 
significant apoptosis. Since apoptosis remained in a very 
low range (1.61 ± 0.36% to 4.02 ± 0.03%) the biological 
role of this elevation is questionable. In case of the mutant 
KRAS-expressing H358 and A549 the level of apoptotic 
fraction showed no significant changes, in the latter cell 
line relatively high level of basic apoptosis was measured 
(Table 2).
Effect of the combination of zoledronic acid with 
cisplatin on the proliferation of human NSCLC 
cell lines
Cisplatin is a commonly used agent in the cytostatic 
therapy of NSCLC. Analyzing the in vitro proliferation 
assay H358 and H1650 showed relative resistance, 
H1975 and LCLC-103H proved to be sensitive, while 
A549 cell line was at the intermediate level. Except for 
A549, combining cisplatin with zoledronic acid the 50% 
inhibitory concentration values (IC50) were reduced in 
all of the studied human NSCLC cell lines, which meant 
additive effect (Table 3).
Effect of zoledronic acid on the in vitro migration 
of human NSCLC cell lines
Zoledronic acid can potentially target different 
regulatory small G proteins involved not only in the 
signalization of proliferation, but also in cell migration. 
In modified Boyden-chamber zoledronic acid inhibited 
migration of the human NSCLC cell lines, irrespectively 
of KRAS-status. However, in the case of KRAS-
mutant cells, only higher concentrations proved to be 
effective. Detected effects were between 40 and 70% of 
untreated controls for all every human NSCLC cell lines 
(Figure 2B).
The in vivo effect of zoledronic acid in 
subcutaneous xenograft model
LCLC-103H, A549 and H1650 tumors were 
subcutaneously transplanted into SCID mice. Then after 21 
days the xenografted mice were treated intraperitoneally 
weekly for three weeks with the human dose and a dose 
ten-fold the human dose of zoledronic acid (50 μg/kg 
and 500 μg/kg) combined with one-tenth of the human 
dose of cisplatin (0.2 mg/kg). Our results showed that 
the highest dose of zoledronic acid significantly reduced 
the weight of LCLC-L03H xenografts compared to that 
of the control group (P=0.032; Kruskal-Wallis test). In 
combination with cisplatin, zoledronic acid showed an 
evident tendency, which however did not prove to be 
statistically significant (Figure 3A). In concodance to our 
in vitro results, H358 xenograft tumor expressing mutant 
KRAS showed significant effect neither to zoledronic acid 
nor cisplatin. Surprisingly, zoledronic acid and cisplatin 
did not decrease the weight of H1650 xenograft tumor 
expressing activating EGFR-mutation.
To reveal the mechanism of the in vivo effect of 
zoledronic acid, xenograft tumors were analyzed by 
immunohistochemistry. The proportion of proliferating 
tumor cells was determined by Ki-67 labeling, which is a 
specific cellular marker for proliferation. In monotherapy 
cisplatin and zoledronic acid significantly inhibited in 
vivo the proportion of cycling LCLC-103H tumor cells, 
however in case of combinatory treatment such an effect 
cannot be detected (Figure 3B).
The in vivo effect of zoledronic acid on the 
vascularisation of human LCLC-103H xenograft was 
analyzed by vessel-specific SMA labeling (Figure 4A). 
SMA (smooth muscle actin) strains smooth muscle, 
which is a critical component in the wall of the vessels. 
Compared to solvent treated control, zoledronic acid 
significantly induced vascularization of subcutaneous 
xenograft at 500 μg/kg dose (39.87 ± 12.84 vs. 51.67 + 
16.98 positive vessels per field of vision, respectively; data 
are mean ± SD, P=0.015, Mann-Whitney’s u test).
Mechanism of the vascular effects of zoledronic 
acid in in vitro models
VEGF is one of the main regulators of angiogenesis. 
The in vitro expression of VEGF in H1975 and LCLC-
103H human NSCLC was measured by real-time PCR. 
In serum-free conditions, 48 hour administration of 
zoledronic acid in 10 or 25 μM significantly increased 
the expression of VEGF in wild type KRAS-expressing 
LCLC-103H cells, while in mutant KRAS carrier H1975 
the effect was not significant, albeit a tendency was 
observable (Figure 4B).
In previous studies it was shown that VEGF induced 
the proliferation of human Kaposi sarcoma cells [29, 30]. 
Since we detected increased level of VEGF in the case 
of zoledronic acid-treated LCLC-103H cells, we have 
generated 10 μM zoledronic acid-induced supernatants in 
serum-free conditions and administered to KS-IMM cells 
for 48 hours. Compared to untreated control cells, we have 
detected that zoledronic acid-induced supernatant increased 
proliferation of human KS-IMM cells in case of supernatant 
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Table 3: The 50% inhibitory concentration (IC50) of cisplatin (in μM) on the proliferation of human NSCLC-lines in 
combination with zoledronic acid
LCLC-103H H1650 H1975 A549 H358
Control 0.19±0.01 4.39±0.21 0.35±0.15 1.27±0.62 8.08±1.51
Zoledronic acid (10 μM) 0.13±0.11* 1.62±0.4* 0.37±0.12 1.7±0.7 4.9±0.71*
Zoledronic acid (25 μM) 0.007±0.003* 0.29±0.11* 0.15±0.07* 1.75±0.89 2.59±0.32*
Zoledronic acid (50 μM) <0.001* 0.26±0.12* 0.024±0.01* 0.89±0.43 1.27±0.26*
In combination, zoledronic acid reduced the concentration of cisplatin for the same inhibitory level (n=5). *: p<0.05 
to untreated control.
Figure 3: The effect of zoledronic acid on subcutaneous xenografts. The highest dose of zoledronic acid (ZA) significantly inhibited 
the growth of subcutaneous LCLC-103H xenograft. However, zoledronic acid proved unable to increase the inhibitory effect of cisplatin 
significantly, albeit the tendency was clear. H358 xenograft tumor expressing mutant KRAS and H160 xenograft tumor expressing activating 
EGFR-mutation did not show significant effect to zoledronic acid or cisplatin A. (Data are means ± SEM, n=8; *: p=0.032 to solvent treated 
control.) Cisplatin significantly inhibited numbers of Ki-67-positive LCLC-103H cells in in vivo xenograft tumor, however zoledronic acid was 
incapable of boosting this effect in the applied doses B. (Data are means ± SEM, n=8*5; *: p<0.05 to solvent treated control.)
Table 2: The in vitro effect of zoledronic acid on the apoptosis of human NSCLC-lines 
LCLC-103H H1650 H1975 A549 H358
Control 1.06±0.35 6.33±0.42 1.61±0.36 6.04±1.65 2.42±1.24
Zoledronic acid (25 μM) 4.68±0.23* 8.72±0.4 1.73±0.28 8.43±2.55 2.82±0.55
Zoledronic acid (50 μM) 4.02±0.28* 7.19±0.17 2.94±0.06 10.6±2.51 4.77±1.46
Zoledronic acid (100 μM) 9.89±1.15* 5.75±1.47 4.02±0.03* 10.01±6.99 6.11±3.29
Statistically and biologically significant apoptosis was measured only in wild type EGFR- and wild type KRAS-expressing 
LCLC-103H. (±SD, n=3). *: p<0.05 to untreated control.
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of the zoledronic acid-treated LCLC-103H cells (127.45 + 
17.75 % of the control; mean ± SD, P=0.0002). Meanwhile, 
zoledronic acid did not affect the proliferation of KS-IMM 
cells directly (data not shown). These findings strengthened 
the theory of the in vivo vascularization-inducing effect of 
zoledronic acid. On the other hand, A549, H358, H1650 and 
H1975 did not show similar effect significantly (Figure 4C).
DISCUSSION
For a long while, the mutation of KRAS-oncogene has 
been in the focus of scientific and clinical interest. The most 
frequent mutation of KRAS is localized in codon 12 (G12C), 
which affects approximately one third of the experimentally 
used NSCLC-lines and 30% of patients with lung cancer 
[6, 31]. The active wild type K-Ras protein is localized 
in the plasma membrane, which requires prenylation by 
farnesyltransferases or geranylgeranyltransferases, [9]. 
Bone metastasis inhibitor zoledronic acid has the potential 
to prevent prenylation of small-G proteins by inhibition 
of farnesyl-diphosphate synthase [12], suggesting the 
anticancer effect of the agent not only on the metastases, but 
directly on the primary tumor as well. Numerous preclinical 
works provided evidence on the anti-proliferative effect of 
zoledronic acid in breast cancer, pancreatic cancer, prostate 
cancer, small and non-small lung cancers under both in vitro 
and in vivo conditions [16-20, 23-25], however, the exact 
explanation of the efficacy is not yet been revealed.
Our systematic analysis demonstrated that the critical 
target of zoledronic acid was K-Ras protein: in human 
NSCL cell lines prenylation of wild type Ras (H1975, 
LCLC-103H) is inhibited by zoledronic acid, leading to 
reduced proliferation capacity, thus treatment in combination 
resulted higher susceptibility against the standard cytotoxic 
drug, cisplatin. On the other hand, exon2/codon12-mutant 
Ras (in H358 and A549) does not need prenylation for its 
activity, therefore usage of zoledronic acid was ineffective 
from this aspect. Surprisingly, zoledronic acid did not inhibit 
Figure 4: The effect of zoledronic acid on the in vivo vascularization of LCLC-103H xenograft and the in vitro modelling 
of this phenomenon. Zoledronic acid enhanced the vascularization of LCLC-103H xenograft. Vessels were labeled by 
immunohistochemistry using anti-smooth muscle actin (SMA). Bars indicate 100 μM A. Zoledronic acid increased the in vitro 
expression of VEGF in LCLC-103H cell line shown by real time PCR, however did not affect the expression in H1975 cell line 
significantly (mean ± SD, n=3). Beta actin served as reference. *: p<0.05 to untreated control B. The proliferation of VEGF-
sensitive KS-IMM (human Kaposi-sarcoma) cells was only induced by the supernatant of zoledronic acid-treated LCLC-103H 
cells. A549, H358, H1650 and H1975 did not show similar significant effect (mean ± SD, n=5). Zoledronic acid was applied on the 
non-small cell lung cancer lines for 48 hours, thereafter filtrated supernatants were applied on KS-IMM cells for another 48 hours C.
Oncotarget79509www.impactjournals.com/oncotarget
prenylation of K-Ras protein in H1650 cells expressing 
activating EGFR-mutation, which suggested that this cells 
did not prefer K-Ras pathway in the signalization of EGFR.
Previous preclinical studies described zoledronic 
acid as an apoptotic agent in human breast cancer and 
pancreatic cancer cell lines [16, 17]. However, in our 
in vitro model zoledronic acid did not induce apoptosis 
in human NSCLC lines, similarly to other works 
focusing on NSCLC [25, 32]. In our xenograft tumors 
immunohistochemistry proved reduced number of Ki-67-
positive cells after treatment with zoledronic acid, which 
corroborates the in vitro findings of Chang et al. and Li 
et al. that the inhibitory effect of the drug emerges rather 
through the blockade of cell cycle than apoptosis [25, 32].
Numerous preclinical data are available on the 
synergistic effect of zoledronic acid with cytostatic agents, 
such as paclitaxel, antracyclins, cisplatin, gemcitabine, 
and topoisomerase inhibitors in human cancer cell lines 
including SCLC [20, 22-24, 33]. Previously in NSCLC 
only one in vitro study proved that zoledronic acid 
enhanced the cytotoxicity of cisplatin in the A549 cell line 
[34], and other works provided data for the synergistic 
effect of zoledronic acid with EGFR-based therapy [25]. 
However, this work is the first to demonstrate the in vivo 
enhancing effect of zoledronic acid with the most widely 
used cytotoxic agent cisplatin. Similarly to our work, a 
previous study showed synergistic effect in A549 cells 
expressing G12C-mutant KRAS, however that set of 
experiments focused only on proliferation and apoptosis 
[34]. According to that paper 100 μM zoledronic acid 
showed 50% cytotoxicity on its own, which contradicts 
our data. Since neither we and nor other previous works 
have observed any significant apoptosis inducing capacity 
of zoledronic acid in human NSCLC cell lines, we assume 
a special experimental model in the background.
Another interesting aspect of the in vivo effect of 
zoledronic acid is angiogenesis. Previous preclinical and 
clinical studies proved that zoledronic acid could be an 
anti-angiogenic agent, which could inhibit proliferation of 
HUVEC endothelial cells, suppress expression of VEGF in 
A549 NSCLC line (with G12S-mutant KRAS), and cause 
decreased level of VEGF in the circulation of cancer patients 
[19, 35]. On the contrary, our work demonstrated elevated 
VEGF-expression in vitro in NSCLC cells carrying wild 
type KRAS, and improved vascularization of xenograft 
tumors in vivo treated by zoledronic acid. However, based 
on our in vitro results, increased proliferation of vascular 
cells were only observed in the case of double wild type 
cells, cells with different genetic background did not show 
this effect. Although numerous paper stated zoladronic 
acid as an anti-angiogenic agent, in parallel with our work 
there were some that proved that in certain environmental 
conditions zoledronic acid could induce VEGF expression. 
Zafar et al. confirmed that zoledronic acid induce VEGF 
expression in human gingival fibroblast [36]. Furthermore, 
other inhibitory agents of prenylation, statins induced 
expression of VEGF [37]. Those papers suggested that in 
the background of induction of VEGF is not related to the 
mevalonate pathway. Since the induction could be attenuated 
by PI3K (phosphoinositid 3-kinase) inhibitor LY294002, 
other signalization mechanism (e.g. PI3K-pathway) was 
suggested.
Previous studies showed the potential benefit of 
angiogenesis in subcutaneous in vivo models on HT25 
colorectal and A431 squamous cell cancer xenograft, 
since increased vascular density promoted the penetration 
of cytostatic agent [38]. In concordance, our in vivo model 
with LCLC-103H the vascularization effect of zoledronic 
acid could contribute to the cytostatic effect of cisplatin. 
It is a well known fact that intratumoral blood vessels 
are frequently immature and leaky causing intratumoral 
hypoxia and resistance to cytostatic effects of drugs. 
Several clinically used “angiogenesis inhibitors” operate 
through vessel normalization, by improving better drug 
penetration into tumors [39]. Here we have used a pericyte 
marker for blood vessel identification. The observed 
paradoxical effect of zoledronic acid on VEGF in wild 
type KRAS expessing NSCLC tumor and its consequences 
on improved vascularization/vessel stabilization may 
easily follow similar biological trends.
According to other studies, nitrogen-containing 
bisphosphonates inhibited adhesion of breast cancer and 
prostatic cancer cells to the elements of the extracellular 
matrix, which prevented invasion and metastasis formation 
of cancer cells [40]. Irrespectively of KRAS-status, 
Zoledronic acid reduced migratory capacity of all the 
applied NSCLC lines, which suggests the inhibition of other 
small G proteins involved in motility signal (such as Rho, 
Rac, Cdc42) by preventing posttranslational prenylation.
MATERIALS AND METHODS
NSCLC cell cultures
The genetic background of the applied human 
NSCLC lines is summarized in Table 1. A549 
adenocarcinoma expressed exon2-mutant KRAS 
(G12S), H358 human bronchioalveolar carcinoma cell 
line expressed exon2-mutant KRAS (G12C), both with 
wild type EGFR. LCLC-103H human large cell line 
expressed wild-type KRAS and wild-type EGFR. H1650 
and H1975 human adenocarcinoma cell lines expressed 
wild-type KRAS, H1650 had an activating exon19 
EGFR-mutation, while H1975 showed resistance against 
EGFR-TKIs due to exon21 mutations. All the cell lines 
were grown in medium RPMI-1640 (Sigma-Aldrich, St. 
Louis, MO) supplemented with 5% fetal calf serum (FCS) 
(Sigma-Aldrich) and 1% penicillin-streptomycin (Sigma-
Aldrich).
Western-blot analysis
After 48 hour incubation with 25 μM zoledronic 
acid or control medium, culture media were replaced 
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with ice-cold phosphate buffered saline, and cells were 
removed from the flask surface using a cell scraper. 
The samples were then centrifuged for 5 minutes at 
300 g on 4°C to precipitate the cells. After discarding 
the supernatant, buffer A was added [10 mM NaCl, 1.5 
mM MgCl2, 10 mM Tris (pH 7.4) containing protease 
inhibitors (8 μg/mL aprotinine, 10 μg/mL leupeptine, 
50 μg/mL PMSF and 2 mM DTT)]. The samples were 
disrupted with a Dounce homogenizer (80 strokes; 
Sigma-Aldrich). Following homogenization, Buffer 
B [525 mM mannitol, 175 mM sucrose, 12.5 mM 
Tris (pH 7.4), and 2.5 mM EDTA containing the same 
concentration of protease inhibitors as buffer A] was 
added in a ratio of 4:10 homogenate/buffer B. To obtain 
membrane and cytosol fractions, total lysates were 
centrifuged at 100,000 g at 4°C for 60 min in a 70.1 
Ti rotor (Beckman), Indianapolis, IN). The organelle 
and membrane samples were diluted 1:1 by 2x Laemmli 
buffer (Sigma-Aldrich), and stored at -80°C until further 
use. The whole separation procedure was performed on 
ice to avoid protein degradation.
Protein content of the samples was measured 
according to the method of Lowry [41]. The proteins 
were separated in a 7.5% SDS-polyacrylamide gel, then 
transferred to a PVDF membrane (Bio-Rad, Hercules, 
CA), using a wet electroblotting apparatus according to 
the manufacturer’s protocols. Primary antibodies used 
during western blot: K-Ras (ab55391, Abcam, Cambridge, 
MA) Na/K-ATPase (BML-SA247-0100, Enzo Life 
Sciences, Farmingdale, NY). Horseradish-peroxidase 
conjugated anti-mouse IgG secondary antibody was 
purchased from Jackson Immuno Research Laboratories. 
Immunoblots were revealed by enhanced WesternBright 
chemiluminescence system (Advansta, Menlo Park, CA). 
Expression of K-Ras was compared to the level of Na/K-
ATPase.
Cell proliferation assay
Cell suspension containing 5x103 viable cells/well 
was plated onto 96-well dishes and allowed to attach 
at 37°C in 5% CO
2
 atmosphere in RPMI-1640 medium 
(Sigma-Aldrich) supplemented with 5% FCS. In case 
of the LCLC-103H cell line, 2.5x103 viable cells/well 
was applied. After 24 hours, cells were exposed to 
different concentrations of cisplatin (“Ebewe” cisplatin, 
Ebewe Pharma, Austria) and zoledronic acid (Zometa®, 
Novartis Pharmaceuticals Inc., Switzerland) for 48 
hours. The effects of the treatments were analyzed 
by MTT (Sigma-Aldrich) colorimetric assay [42].
The results of three independent experiments 
were transferred to 50% inhibitory concentrations 
(IC50), which were calculated by Dose-Effect Analysis 
with Microcomputers software (Elsevier-Biosoft, 
Cambridge, UK).
Flow cytometric measurement for apoptosis
Cell suspension containing 3x105 viable cells/well 
was plated in 6-well dishes and allowed to attach for 
24 hours at 37°C in 5% CO
2
 atmosphere in RPMI-1640 
medium (Sigma-Aldrich) supplemented with 5% FCS 
(Sigma-Aldrich). In case of the LCLC-103H cell line we 
applied 1.5x105viable cells/ml. After the medium was 
changed (5% FCS) the cells were exposed to different 
concentrations of zoledronic acid for 48 hours. Then the 
treated cells were detached with 0.02% EDTA, washed 
with PBS and then fixed with 70% ethanol. According 
to the protocol of the manufacturer, after several hour 
incubation period with propidium-iodide and RNAse 
(CyStain PI Absolute T, Partec, Germany), we quantified 
the DNA in the cells by flow cytometer (CyFlow, Partec). 
The percentage of apoptotic cells was shown by the sub 
G1 fraction which was analyzed using FlowMax software 
(Partec) [43].
Modified Boyden-chamber migration assay
Cell migration procedure was assayed by a method 
reported previously by Albini et al [44]. We used 96-well 
CXF8 plate (polycarbonate filter with 8 μm pore size, 
Neuroprobe Inc., Cabin John, MD). Previously cultured 
cells were harvested with 0.02% EDTA, washed twice 
with serum free medium and resuspended at 106cells/ml in 
medium with 0.1% BSA containing treatment material. In 
case of the LCLC-103H cell line we started with 0,5x106 
viable cells/ml. The cell suspension (20 μl) was placed 
onto the membrane (Neuroprobe) in the presence of the 
treatment agent and the lower compartment was filled 
with 30 μl of fibronectin (100 μg/ml) (Sigma-Aldrich). 
Cells were allowed to migrate for 24 hours at 37°C in a 
humidified atmosphere containing 5% CO
2
, then cells on 
the upper surface of the filter were removed mechanically, 
the membranes were stained with toluidin blue, and the 
cells in fields of vision were counted manually under light 
microscope.
Subcutaneous xenograft model
Previously in vivo subcutaneously cultured LCLC-
103H, A549 and H1650 human NSCLC tumors were 
subcutaneously transplanted in male BALB/c SCID mice; 
the animals were used at 2-3 months of age. Sizes of 16 
mm3 tumor per animal were implanted subcutaneously 
during anaesthetized state. At day 21, after randomization 
animals were treated intraperitoneally with the human 
dose and a dose ten-fold the human dose of zoledronic 
acid (50 μg/kg and 500 μg/kg) combined with one-tenth of 
the human dose of cisplatin (0.2 mg/kg) weekly for three 
weeks. Controls received 0.9% NaCl in the same volume. 
At day 41 animals were sacrificed by Nembutal (Serva, 
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Heidelberg, Germany) overdose. Subcutaneous tumors 
were removed and the tumor weights were measured. 
The xenograft tumors were fixed in 10% neutral buffered 
formalin.
Immunohistochemistry
Monoclonal mouse antibody against human Ki-
67 (DAKO, Denmark) and human smooth muscle actin 
(SMA) (DAKO) were applied. The routinely formalin-
fixed xenograft tumors were dehydrated in a graded series 
of ethanol, infiltrated with xylene and embedded into 
paraffin at a temperature not exceeding 60°C. Three to four 
micron thick sections were mounted on Superfrost slides 
(Thermo Shandon, Runcorn, UK) and were manually 
deparaffinized. To block endogenous peroxidase activity, 
slides were treated for 5 min at room temperature with 
3% H
2
O
2
 in methanol. Slides were immersed in 0.05 mM 
citrate buffer (pH=6) and exposed to 750 W microwave 
for 3x5 min (MFX-800-3 automatic microwave, Meditest, 
Budapest, Hungary).
Slides were primarily treated with antibody against 
human Ki-67 (1:40) or SMA (1:100) and incubated 
for 1 hour at room temperature. After washing with 
phosphate-buffer-saline, secondary antibody Biotinylated 
Link (Dako) was applied and incubation occurred for 
10 minutes at room temperature. After washing periods 
for visualization, a standard avidin-biotin peroxidase 
technique (ABC system, DAKO) was used with 
diaminobenzidine as chromogen.
The Ki-67-positive tumor cells or SMA-positive 
vessels per fields of vision were counted manually under 
light microscope (200-fold magnification), 5 fields of 
vision per tumor were evaluated.
Effect of zoledronic acid-treatment on the 
VEGF-production of human lung cancer 
cell lines
Previously cultured human lung cancer H1975 and 
LCLC-103H cells were plated on 25 cm2 tissue culture 
flasks (5x105cells/flask) in RPMI supplemented with 5% 
FCS and were allowed to grow. After two days cells were 
treated for 48 hours with 10 or 25 μM of zoledronic acid 
in serum-free conditions. The treated cells were compared 
to untreated control.
Total RNA was extracted from the cells using 
TRI ReagentTM (Sigma-Aldrich) according to the 
manufacturer’s protocol. Possible DNA contamination 
was eliminated using TURBO DNA-freeTM kit (Ambion®). 
Three μg of total RNA were reverse transcribed from each 
sample using deoxy-NTPs (Promega, 0.5 mM each), a 
mixture of random primer and oligo dT (Promega, final 
concentration 3 μM), RNasin® ribonuclease inhibitor 
(Promega, 20 U/reaction), M-MLV RT 5x Reaction Buffer 
(Promega, containing 250 mM Tris-HCl, pH 8.3, 375 mM 
KCl and 15 mM MgCl
2
 and 50 mM DTT) and M-MLV 
Reverse Transcriptase RNase H Minus, Point Mutant 
(Promega, 200 U/reaction). RNA-solutions with the oligos 
were pre-incubated for 5 min at 70°C, then after cooling 
down and adding the dNTPs and enzymes the incubation 
continued for 10 min at 25°C, then 50 min at 45°C. To 
inactivate the reaction the mixture was heated to 70°C for 
15 min.
The real-time PCR analysis was standardized 
by co-amplifying the genes of interest with the 
housekeeping gene β-actin (Applied Biosystems 
Taqman probe: Hs03023880_g1). The real-time PCR 
reaction was run on the Applied Biosystem’s 7500 Real-
Time PCR System. The reaction mixture contained the 
followings: VEGF Taqman probe (Hs00900054_m1, 
Applied Biosystems), TaqMan® Universal PCR Master 
Mix (Applied Biosystems) and 2 μg cDNA. No template 
control (containing water) was used as negative control 
for the different primer-pairs. The cycling parameters 
were 50°C (2 min), 95°C (10 min), 40 cycles of 95°C 
(15 sec) and 60°C (1 min). The starting quantity of 
gene expression in the samples was determined by 
comparison of unknowns to a standard curve generated 
from a dilution series of template DNA of known 
concentrations, and normalized to their own β-actin 
expression.
Effect of the supernatant of treated LCLC-103H 
cells on the proliferation of KS cells
KS-IMM (human Kaposi sarcoma cell line) [45], 
LCLC-103H, H358, A549, H1650 and H1975 cells were 
previously cultured in RPMI-1640 medium (Sigma-
Aldrich) supplemented with 5% FCS (37°C and 5% 
CO
2
 atmosphere). Cell suspension containing 5x104/well 
viable LCLC-103H, H358, A549, H1650 and H1975 cells 
were plated in 6-well dishes and allowed to attach. After 
24 hours the cells were exposed to 10 μM of zoledronic 
acid for 48 hours. The filtrated supernatant of treated and 
untreated cells was placed onto cultured KS-IMM cells 
in 96-well dishes. Previously the KS-IMM cells were 
allowed to attach for 48 hours in the concentration of 
5x104viable cells/ml in 96-well dishes. We treated the KS-
IMM cells with supernatant for 48 hours in serum-free 
conditions. The effects were analyzed by MTT (Sigma-
Aldrich) colorimetric assay, as detailed above.
Statistics
To determine statistical differences between groups, 
ANOVA was used with post hoc Scheffé-test, where 
parametric methods were available. In case of the animal 
experiments we used non-parametric Kruskal-Wallis test. 
Statistical significance was determined when Ps were 
<0.05. Statistical analysis was performed by Statistica 
12.0 (StatSoft, USA, Tulsa, OK).
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